The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to BRCA2 Protein

This is a "connection" page, showing publications Olufunmilayo Olopade has written about BRCA2 Protein.
Connection Strength

6.862
  1. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
    View in: PubMed
    Score: 0.621
  2. Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer. 2018 10; 17(4):471-483.
    View in: PubMed
    Score: 0.586
  3. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
    View in: PubMed
    Score: 0.575
  4. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
    View in: PubMed
    Score: 0.449
  5. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
    View in: PubMed
    Score: 0.380
  6. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
    View in: PubMed
    Score: 0.369
  7. The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
    View in: PubMed
    Score: 0.196
  8. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res Treat. 2022 Jun; 193(2):485-494.
    View in: PubMed
    Score: 0.187
  9. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.173
  10. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
    View in: PubMed
    Score: 0.158
  11. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.156
  12. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum Mutat. 2019 11; 40(11):e1-e23.
    View in: PubMed
    Score: 0.155
  13. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796.
    View in: PubMed
    Score: 0.154
  14. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.152
  15. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
    View in: PubMed
    Score: 0.150
  16. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620.
    View in: PubMed
    Score: 0.141
  17. Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. J Med Genet. 2016 08; 53(8):548-58.
    View in: PubMed
    Score: 0.123
  18. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
    View in: PubMed
    Score: 0.122
  19. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.120
  20. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
    View in: PubMed
    Score: 0.116
  21. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71.
    View in: PubMed
    Score: 0.113
  22. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
    View in: PubMed
    Score: 0.111
  23. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.107
  24. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011 Nov; 130(5):685-99.
    View in: PubMed
    Score: 0.088
  25. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):1032-8.
    View in: PubMed
    Score: 0.087
  26. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
    View in: PubMed
    Score: 0.086
  27. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
    View in: PubMed
    Score: 0.085
  28. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
    View in: PubMed
    Score: 0.081
  29. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
    View in: PubMed
    Score: 0.077
  30. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
    View in: PubMed
    Score: 0.070
  31. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
    View in: PubMed
    Score: 0.069
  32. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord. 2007 Sep; 8(3):255-67.
    View in: PubMed
    Score: 0.067
  33. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
    View in: PubMed
    Score: 0.053
  34. Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
    View in: PubMed
    Score: 0.052
  35. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
    View in: PubMed
    Score: 0.051
  36. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology. 2002 Nov; 225(2):519-26.
    View in: PubMed
    Score: 0.049
  37. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
    View in: PubMed
    Score: 0.045
  38. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2021 11; 30(11):2038-2043.
    View in: PubMed
    Score: 0.045
  39. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001 Jun 28; 344(26):2028-9.
    View in: PubMed
    Score: 0.044
  40. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
    View in: PubMed
    Score: 0.042
  41. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
    View in: PubMed
    Score: 0.042
  42. Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet. 2000 Aug; 107(2):192-4.
    View in: PubMed
    Score: 0.042
  43. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
    View in: PubMed
    Score: 0.041
  44. Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: feature selection. Med Phys. 2000 Jan; 27(1):4-12.
    View in: PubMed
    Score: 0.040
  45. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
    View in: PubMed
    Score: 0.040
  46. Two truncating variants in FANCC and breast cancer risk. Sci Rep. 2019 08 29; 9(1):12524.
    View in: PubMed
    Score: 0.039
  47. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
    View in: PubMed
    Score: 0.033
  48. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.025
  49. Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging. 2008 Jun; 21(2):145-52.
    View in: PubMed
    Score: 0.017
  50. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
    View in: PubMed
    Score: 0.015
  51. Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys. 2004 Mar; 31(3):549-55.
    View in: PubMed
    Score: 0.013
  52. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.